A prospective multi-center study to investigate the EGFR-TKI resistance profile, treatment algorithm and clinical outcome in Chinese patients with advanced EGFRm1 NSCLC who have received prior first generation EGFR TKI (PRECENT study, CCTC-1601, NCT02988141)
机构：[1]Thoracic Oncology, The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, China,[2]Hunan Province Tumor Hospital, Changsha, China,[3]Hainan General Hospital, Hainan, China,[4]Yunnan Tumour Hospital (3rd Affiliated Hospital Affiliated to Kunming Medical College), Kunming, China,[5]Shenzhen People’s Hospital, Shenzhen, China,深圳市人民医院[6]Cancer Centre Sun Yat-Sen University, Guangzhou, China,[7]Department of Thoracic Surgery/Oncology, The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
出处：
ISSN：
基金：
AstraZeneca
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2017]版：
大类|1 区医学
小类|1 区肿瘤学
最新[2023]版：
大类|1 区医学
小类|1 区肿瘤学
第一作者：
第一作者机构：[1]Thoracic Oncology, The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, China,
推荐引用方式(GB/T 7714)：
W. Liang,L. Wu,L. Wang,et al.A prospective multi-center study to investigate the EGFR-TKI resistance profile, treatment algorithm and clinical outcome in Chinese patients with advanced EGFRm1 NSCLC who have received prior first generation EGFR TKI (PRECENT study, CCTC-1601, NCT02988141)[J].ANNALS OF ONCOLOGY.2017,28:-.
APA：
W. Liang,L. Wu,L. Wang,Y. Huang,R. Xu...&J. He.(2017).A prospective multi-center study to investigate the EGFR-TKI resistance profile, treatment algorithm and clinical outcome in Chinese patients with advanced EGFRm1 NSCLC who have received prior first generation EGFR TKI (PRECENT study, CCTC-1601, NCT02988141).ANNALS OF ONCOLOGY,28,
MLA：
W. Liang,et al."A prospective multi-center study to investigate the EGFR-TKI resistance profile, treatment algorithm and clinical outcome in Chinese patients with advanced EGFRm1 NSCLC who have received prior first generation EGFR TKI (PRECENT study, CCTC-1601, NCT02988141)".ANNALS OF ONCOLOGY 28.(2017):-
医学